The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into ...

House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review ...

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

Spring House, Pennsylvania Saturday, January 11, 2025, 12:00 Hrs [IST] ...

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases ...

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug ... "best-in-class potential" for the drug, which Sanofi licensed from ...

Anti-drug antibodies were produced at similar levels to Humira, but with no impact on safety and pharmacokinetics, Moses added. Ablynx noted that the placebo effect was highest in a group of ...